Related Experiment Video
Updated: Aug 6, 2026
09:24
In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration
Published on: February 23, 2019
Arsenic-induced APL differentiation in cerebrospinal fluid
Annett Helwig1, Matthias Klemm, Reinhard Schüttig
1Medical Clinic and Policlinic I, University Hospital of the Technical University, Fetscherstrasse 74, 01307 Dresden, Germany.
Leukemia Research
|August 1, 2006
Summary
Arsenic trioxide effectively treats acute promyelocytic leukemia (APL) that spreads to the central nervous system (CNS). This study shows the drug crosses the blood-brain barrier, offering new hope for extramedullary APL patients.
Area of Science:
- Hematology
- Oncology
- Neuroscience
Background:
- Acute promyelocytic leukemia (APL) CNS involvement historically portends a poor prognosis.
- Despite advances, treating APL with central nervous system (CNS) disease remains challenging.
Observation:
- A patient with relapsed APL primarily affecting the CNS was treated.
- Arsenic trioxide administration resulted in significant morphological changes in CNS cellularity.
Findings:
- The observed changes were consistent with a differentiation syndrome induced by arsenic trioxide.
- Detection of arsenic trioxide within the CNS confirmed its ability to cross the blood-brain barrier.
Implications:
- Arsenic trioxide demonstrates efficacy in treating extramedullary APL, specifically CNS involvement.
- This finding supports arsenic trioxide as a therapeutic option for APL patients with CNS disease.
- The study provides evidence for the potential of arsenic trioxide in overcoming the blood-brain barrier in APL treatment.
